Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06427668
PHASE2

Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

Sponsor: Spinogenix

View on ClinicalTrials.gov

Summary

This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.

Official title: A Phase 2, Randomized, Placebo-controlled, Double-Blind Multicenter Study to Assess the Safety, Tolerability, and Pharmacodynamics (PD) in Adult Participants With Mild-to Moderate Alzheimer's Disease (AD) Administered SPG302

Key Details

Gender

All

Age Range

45 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2024-07-29

Completion Date

2026-06

Last Updated

2025-08-17

Healthy Volunteers

No

Interventions

DRUG

SPG302

synthetic small molecule

DRUG

Placebo

Placebo

Locations (2)

St Vincent's Hospital

Sydney, New South Wales, Australia

Flinders Medical center

Adelaide, South Australia, Australia